Karim Mikhail, Amarin CEO
June 6, 2022 10:37 AM EDT
People
R&D

Amarin CFO re­signs amid cost-cut­ting mea­sures, staff re­duc­tion of 40%

Paul Schloesser

Associate Editor

A year af­ter a Supreme Court opin­ion put the fi­nal nail in the cof­fin for Amarin’s fish-oil heart drug, the biotech is mak­ing some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times